R
Robin M. Murray
Researcher at King's College London
Publications - 1583
Citations - 128883
Robin M. Murray is an academic researcher from King's College London. The author has contributed to research in topics: Psychosis & Schizophrenia. The author has an hindex of 171, co-authored 1539 publications receiving 116362 citations. Previous affiliations of Robin M. Murray include University of Cambridge & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
The impact of molecular genetics on our understanding of the psychoses.
Michael Mullan,Robin M. Murray +1 more
TL;DR: This article reviews the findings, and explores the increasing contribution of the ‘new genetics' to the understanding of the organic and functional psychoses.
Journal ArticleDOI
The relative prevalence of schizophrenia among cannabis and cocaine users attending addiction services.
TL;DR: The prevalence of schizophrenia and to a lesser extent affective disorders is higher among people with cannabis use disorder than cocaine use disorder among those attending addiction services.
Journal ArticleDOI
Remission and recovery from first-episode psychosis in adults: A systematic review and meta-analysis of long-term outcome studies
John Lally,John Lally,Olesya Ajnakina,Brendon Stubbs,M. Cullinane,Kieran C. Murphy,Fiona Gaughran,Robin M. Murray +7 more
TL;DR: The data suggest that remission and recovery rates in FEP may be more favorable than previously thought, and stability of recovery rates after the first two years is observed, suggesting that a progressive deteriorating course of illness is not typical.
Journal ArticleDOI
Genetic copy number variants, cognition and psychosis: a meta-analysis and a family study.
Johan H. Thygesen,Amelia Presman,Jasmine Harju-Seppänen,Haritz Irizar,Rebecca M. Jones,Karoline Kuchenbaecker,Kuang Lin,Kuang Lin,Behrooz Z. Alizadeh,Isabelle Austin-Zimmerman,Agna A. Bartels-Velthuis,Anjali Bhat,Richard Bruggeman,Richard Bruggeman,Wiepke Cahn,Stella Calafato,Benedicto Crespo-Facorro,Benedicto Crespo-Facorro,Lieuwe de Haan,Sonja M C de Zwarte,Marta Di Forti,Alvaro Diez-Revuelta,Alvaro Diez-Revuelta,Jeremy Hall,Mei-Hua Hall,Conrad Iyegbe,Assen Jablensky,René S. Kahn,René S. Kahn,Luba Kalaydjieva,Eugenia Kravariti,Stephen M. Lawrie,Jurjen J. Luykx,Ignacio Mata,Colm McDonald,Andrew M. McIntosh,Andrew M. McIntosh,Andrew McQuillin,Rebecca Muir,Roel A. Ophoff,Roel A. Ophoff,Roel A. Ophoff,Marco Picchioni,Diana Prata,Diana Prata,Diana Prata,Siri Ranlund,Siri Ranlund,Dan Rujescu,Dan Rujescu,Bart P. F. Rutten,Katja Schulze,Katja Schulze,Madiha Shaikh,Frederike Schirmbeck,Claudia J. P. Simons,Timothea Toulopoulou,Timothea Toulopoulou,Therese van Amelsvoort,Neeltje E.M. van Haren,Neeltje E.M. van Haren,Jim van Os,Jim van Os,Ruud van Winkel,Evangelos Vassos,Muriel Walshe,Matthias Weisbrod,Eirini Zartaloudi,Vaughan Bell,John Powell,Cathryn M. Lewis,Robin M. Murray,Robin M. Murray,Elvira Bramon,Elvira Bramon +74 more
TL;DR: The findings show that the known high-risk CNVs are not only associated with schizophrenia and other neurodevelopmental disorders, but are also a contributing factor to impairment in cognitive domains such as memory and perceptual reasoning, and act as intermediate biomarkers of disease risk.
MonographDOI
First Episode Psychosis
TL;DR: It is necessary to consider the context in which the individual is diagnosed, as well as the individual’s prior medical history, to arrive at a diagnosis and treatment strategy.